Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodine I 131 Tositumomab vs Ibritumomab Tiuxetan in Relapsed/Transformed Follicular Lymphoma
NCT00319332Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Sep 2005
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of iodine i 131 tositumomab in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by GSK. Planned start Sep 2005; status: withdrawn.
02
Drugs
iodine i 131 tositumomab
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00319332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319332.